Dual glucagon/GLP-1 receptor agonist for metabolic disease and NASH.
TL;DR — Survodutide is a metabolic & weight peptide with a typical starting dose of 2.4 mg. For a 5 mg vial, add 1 mL bacteriostatic water to yield 5 mg/mL.
Add 1 mL of bacteriostatic water to a 5 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 5 mg/mL.
What is the recommended dose of Survodutide?
A typical research dose is 2.4 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a Survodutide vial?
A 5 mg vial reconstituted with 1 mL BAC water yields approximately 2 doses at 2.4 mg each.
Peptide Intelligence
What receptors does Survodutide target?
Survodutide is a dual glucagon/GLP-1 receptor agonist. Glucagon receptor activation drives hepatic fat clearance and energy expenditure, making it particularly relevant for NASH/MASH research alongside metabolic weight management.
What is the half-life of Survodutide?
Survodutide has a half-life supporting once-weekly dosing, estimated at approximately 5–7 days based on phase 2 pharmacokinetic data. Dose escalation over several months is standard in research protocols.
How does Survodutide compare to GLP-1 mono-agonists for liver fat?
Survodutide showed superior liver fat reduction versus GLP-1 mono-agonists in NASH trials. Phase 2 data showed greater than 50% liver fat reduction in a majority of subjects at maximal doses, attributed to glucagon receptor-driven hepatic fat oxidation.